Loan Hoang-Sayag
Director/Board Member at Orano Med SAS
Loan Hoang-Sayag active positions
Companies | Position | Start | End |
---|---|---|---|
Andera Partners SCA
Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Private Equity Investor | 01/11/2018 | - |
Orano Med SAS
Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France. | Director/Board Member | - | - |
Career history of Loan Hoang-Sayag
Former positions of Loan Hoang-Sayag
Companies | Position | Start | End |
---|---|---|---|
CELLECTIS S.A. | Chief Tech/Sci/R&D Officer | 08/01/2016 | 05/10/2017 |
MEDIAN TECHNOLOGIES | Chief Tech/Sci/R&D Officer | 26/10/2017 | - |
Quintiles Transnational Corp.
Quintiles Transnational Corp. Miscellaneous Commercial ServicesCommercial Services Quintiles Transnational Corp. provides biopharmaceutical development and commercial outsourcing services. It offers product development and integrated healthcare services, including commercial and observational solutions. The company was founded by Dennis B. Gillings and Gary Koch in September 1990 and is headquartered in Durham, NC. | Chief Tech/Sci/R&D Officer | - | - |
Training of Loan Hoang-Sayag
Sorbonne Université | Graduate Degree |
Statistics
International
France | 6 |
United States | 2 |
Operational
Chief Tech/Sci/R&D Officer | 3 |
Private Equity Investor | 1 |
Graduate Degree | 1 |
Sectoral
Health Technology | 3 |
Commercial Services | 2 |
Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
CELLECTIS S.A. | Health Technology |
MEDIAN TECHNOLOGIES | Health Services |
Private companies | 3 |
---|---|
Quintiles Transnational Corp.
Quintiles Transnational Corp. Miscellaneous Commercial ServicesCommercial Services Quintiles Transnational Corp. provides biopharmaceutical development and commercial outsourcing services. It offers product development and integrated healthcare services, including commercial and observational solutions. The company was founded by Dennis B. Gillings and Gary Koch in September 1990 and is headquartered in Durham, NC. | Commercial Services |
Andera Partners SCA
Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Finance |
Orano Med SAS
Orano Med SAS BiotechnologyHealth Technology Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France. | Health Technology |
- Stock Market
- Insiders
- Loan Hoang-Sayag
- Experience